Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR; RELAX-AHF Investigators. Metra M, et al. Among authors: cotter g. J Am Coll Cardiol. 2013 Jan 15;61(2):196-206. doi: 10.1016/j.jacc.2012.11.005. J Am Coll Cardiol. 2013. PMID: 23273292 Free article. Clinical Trial.
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, Caspi A. Cotter G, et al. Eur J Heart Fail. 2001 Aug;3(4):457-61. doi: 10.1016/s1388-9842(01)00168-4. Eur J Heart Fail. 2001. PMID: 11511432 Free article. Clinical Trial.
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G. Kaluski E, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jan 15;41(2):204-10. doi: 10.1016/s0735-1097(02)02708-0. J Am Coll Cardiol. 2003. PMID: 12535809 Free article. Clinical Trial.
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Torre-Amione G, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jul 2;42(1):140-7. doi: 10.1016/s0735-1097(03)00556-4. J Am Coll Cardiol. 2003. PMID: 12849674 Free article. Clinical Trial.
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, Zimlichman R, Vered Z. Kaluski E, et al. Among authors: cotter g. Cardiology. 2008;109(4):273-80. doi: 10.1159/000107791. Epub 2007 Sep 17. Cardiology. 2008. PMID: 17873492 Clinical Trial.
The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators, and Coordinators. Cotter G, et al. J Card Fail. 2008 Oct;14(8):631-40. doi: 10.1016/j.cardfail.2008.08.010. Epub 2008 Sep 14. J Card Fail. 2008. PMID: 18926433 Clinical Trial.
308 results